Prostate Cancer - Results from #340

Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study. October 30, 2024

What's in a Name? Why Words Matter in Advanced Prostate Cancer. October 30, 2024

Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? October 29, 2024

Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. October 29, 2024

The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). October 29, 2024

Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer. October 29, 2024

Trends in Age and Prostate-Specific Antigen at Prostate Cancer Diagnosis between 2010 and 2019. October 29, 2024

Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. October 28, 2024

The hidden costs: a qualitative analysis exploring the experience of prostate cancer treatment-related side effects on sexual function and urinary incontinence among Black survivors and their caregivers. October 28, 2024

Profiling of urinary extracellular vesicle protein signatures from patients with cribriform and intraductal prostate carcinoma in a cross-sectional study. October 28, 2024

Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. October 28, 2024

Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer. October 28, 2024

N-linked fucosylated glycans are biomarkers for prostate cancer with a neuroendocrine and metastatic phenotype. October 25, 2024

The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE). October 25, 2024

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. October 25, 2024

Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy. October 25, 2024

The use of focal therapy for the treatment of prostate cancer in Canada: Where are we, how did we get here, and where are we going? October 25, 2024

The homeodomain regulates stable DNA binding of prostate cancer target ONECUT2. October 24, 2024

Clinical Factors Associated with Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA <0.5 ng/mL. October 24, 2024

Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards. October 24, 2024

Page 18 of 1451